We’re pleased to see our clinical research featured on the website of our longstanding partner, Bedrocan. The article titled “No significant gender differences were observed with advanced cannabinoid inhaler” presents findings from a Syqe®’s study showing that women and men similarly respond to medical cannabis when delivered through the SyqeAir Inhaler that contains Bedrocan® flos.
The publication reflects our shared commitment with Bedrocan to advancing evidence-based cannabis medicine, with a focus on consistent dosing and patient safety.
